Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong · Delayed Price · Currency is HKD 30.16
-1.84 (-5.75%)
Nov 21, 2025, 11:59 AM HKT
HKG:2315 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 1,191 | 980.45 | 716.91 | 533.88 | 354.56 | 253.54 | |
Revenue Growth (YoY) | 48.76% | 36.76% | 34.28% | 50.58% | 39.84% | - |
Cost of Revenue | 244.44 | 204.74 | 206 | 138.21 | 97.3 | 67.34 |
Gross Profit | 946.48 | 775.71 | 510.91 | 395.67 | 257.25 | 186.2 |
Selling, General & Admin | 341.01 | 311.35 | 349.09 | 313.66 | 230.15 | 277.07 |
Research & Development | 371.36 | 323.93 | 474.37 | 699.17 | 558.49 | 276.31 |
Other Operating Expenses | -9.83 | -9.72 | -21.04 | -12.56 | -12.32 | -4.6 |
Operating Expenses | 702.53 | 625.56 | 802.41 | 1,000 | 776.32 | 548.77 |
Operating Income | 243.95 | 150.16 | -291.5 | -604.6 | -519.07 | -362.57 |
Interest Expense | -74.87 | -91.68 | -99.84 | -56.14 | -39.43 | -22.54 |
Interest & Investment Income | 4.81 | 5.9 | 10.16 | 2.17 | 12.51 | 5.75 |
Earnings From Equity Investments | -32.52 | -29.75 | -10.03 | -14.77 | -0.4 | 0.09 |
Currency Exchange Gain (Loss) | 4.6 | 8.67 | 9.08 | 27.37 | -1.78 | -6.59 |
Other Non Operating Income (Expenses) | - | - | - | - | - | -95.82 |
EBT Excluding Unusual Items | 145.96 | 43.29 | -382.14 | -645.97 | -548.16 | -481.68 |
Gain (Loss) on Sale of Investments | 2.75 | -0.36 | 0.15 | 19.27 | 2.13 | 6.19 |
Gain (Loss) on Sale of Assets | 0.93 | 0.01 | 1.83 | 25.35 | 0.39 | -1.2 |
Pretax Income | 149.64 | 42.94 | -380.16 | -601.35 | -545.64 | -476.69 |
Income Tax Expense | 17.43 | 9.4 | 2.8 | 0.8 | - | - |
Earnings From Continuing Operations | 132.21 | 33.54 | -382.95 | -602.16 | -545.64 | -476.69 |
Minority Interest in Earnings | 0.01 | 0.01 | 0 | 0.21 | 0.07 | 48.6 |
Net Income | 132.21 | 33.54 | -382.95 | -601.95 | -545.58 | -428.09 |
Preferred Dividends & Other Adjustments | - | - | - | - | - | -210.84 |
Net Income to Common | 132.21 | 33.54 | -382.95 | -601.95 | -545.58 | -217.26 |
Shares Outstanding (Basic) | 397 | 398 | 398 | 381 | 362 | 129 |
Shares Outstanding (Diluted) | 397 | 398 | 398 | 381 | 362 | 129 |
Shares Change (YoY) | -0.31% | -0.08% | 4.54% | 5.13% | 180.82% | - |
EPS (Basic) | 0.33 | 0.08 | -0.96 | -1.58 | -1.51 | -1.68 |
EPS (Diluted) | 0.33 | 0.08 | -0.96 | -1.58 | -1.51 | -1.68 |
Free Cash Flow | 338.66 | 174.12 | -203.26 | -543.54 | -564.45 | -521.73 |
Free Cash Flow Per Share | 0.85 | 0.44 | -0.51 | -1.43 | -1.56 | -4.04 |
Gross Margin | 79.47% | 79.12% | 71.27% | 74.11% | 72.56% | 73.44% |
Operating Margin | 20.48% | 15.32% | -40.66% | -113.25% | -146.40% | -143.00% |
Profit Margin | 11.10% | 3.42% | -53.42% | -112.75% | -153.88% | -85.69% |
Free Cash Flow Margin | 28.44% | 17.76% | -28.35% | -101.81% | -159.20% | -205.78% |
EBITDA | 382.48 | 289.05 | -154.78 | -465.86 | -415.47 | -328.64 |
EBITDA Margin | 32.12% | 29.48% | -21.59% | -87.26% | -117.18% | -129.62% |
D&A For EBITDA | 138.52 | 138.89 | 136.73 | 138.74 | 103.6 | 33.93 |
EBIT | 243.95 | 150.16 | -291.5 | -604.6 | -519.07 | -362.57 |
EBIT Margin | 20.48% | 15.32% | -40.66% | -113.25% | -146.40% | -143.00% |
Effective Tax Rate | 11.65% | 21.90% | - | - | - | - |
Advertising Expenses | - | - | - | - | - | 3.1 |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.